JPWO2023014727A5 - - Google Patents
Info
- Publication number
- JPWO2023014727A5 JPWO2023014727A5 JP2024506528A JP2024506528A JPWO2023014727A5 JP WO2023014727 A5 JPWO2023014727 A5 JP WO2023014727A5 JP 2024506528 A JP2024506528 A JP 2024506528A JP 2024506528 A JP2024506528 A JP 2024506528A JP WO2023014727 A5 JPWO2023014727 A5 JP WO2023014727A5
- Authority
- JP
- Japan
- Prior art keywords
- cpf1
- population
- grna
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163228509P | 2021-08-02 | 2021-08-02 | |
| US63/228,509 | 2021-08-02 | ||
| US202163278899P | 2021-11-12 | 2021-11-12 | |
| US63/278,899 | 2021-11-12 | ||
| PCT/US2022/039192 WO2023014727A1 (en) | 2021-08-02 | 2022-08-02 | Systems and methods for the treatment of hemoglobinopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024528967A JP2024528967A (ja) | 2024-08-01 |
| JP2024528967A5 JP2024528967A5 (https=) | 2025-08-08 |
| JPWO2023014727A5 true JPWO2023014727A5 (https=) | 2025-08-08 |
Family
ID=83050049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506528A Pending JP2024528967A (ja) | 2021-08-02 | 2022-08-02 | ヘモグロビン異常症の治療のためのシステム及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240335476A1 (https=) |
| EP (1) | EP4381068A1 (https=) |
| JP (1) | JP2024528967A (https=) |
| KR (1) | KR20240043772A (https=) |
| AU (1) | AU2022325054A1 (https=) |
| CA (1) | CA3226886A1 (https=) |
| WO (1) | WO2023014727A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4630554A1 (en) * | 2022-12-05 | 2025-10-15 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| WO2026027887A2 (en) * | 2024-08-02 | 2026-02-05 | Mina Therapeutics Limited | Hbg1/2-sarna compositions and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
| WO2015138510A1 (en) | 2014-03-10 | 2015-09-17 | Editas Medicine., Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
| CA2963820A1 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| AU2016261358B2 (en) | 2015-05-11 | 2021-09-16 | Editas Medicine, Inc. | Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells |
| CN110382692A (zh) | 2016-04-19 | 2019-10-25 | 博德研究所 | 新型crispr酶以及系统 |
| WO2019178426A1 (en) * | 2018-03-14 | 2019-09-19 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| EP4069829A1 (en) | 2019-12-08 | 2022-10-12 | Editas Medicine, Inc. | Modified cells and methods for the treatment of hemoglobinopathies |
-
2022
- 2022-08-02 JP JP2024506528A patent/JP2024528967A/ja active Pending
- 2022-08-02 KR KR1020247006536A patent/KR20240043772A/ko active Pending
- 2022-08-02 CA CA3226886A patent/CA3226886A1/en active Pending
- 2022-08-02 EP EP22758343.2A patent/EP4381068A1/en active Pending
- 2022-08-02 WO PCT/US2022/039192 patent/WO2023014727A1/en not_active Ceased
- 2022-08-02 US US18/294,995 patent/US20240335476A1/en active Pending
- 2022-08-02 AU AU2022325054A patent/AU2022325054A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025081309A5 (https=) | ||
| CA3224970A1 (en) | Compositions and methods for efficient genome editing | |
| JPWO2019178426A5 (https=) | ||
| WO2020063520A1 (zh) | 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用 | |
| AU2015330699A1 (en) | Compositions and methods for promoting homology directed repair | |
| WO2022159758A1 (en) | Novel engineered and chimeric nucleases | |
| WO2025001498A1 (zh) | 工程化的腺苷脱氨酶及碱基编辑器 | |
| US20250243515A1 (en) | Nucleases and compositions, systems, and methods thereof | |
| CN111304258A (zh) | Ndufs2基因条件性点突变小鼠模型及其构建方法和应用 | |
| CN121889499A (zh) | 用于治疗α1-抗胰蛋白酶缺乏症的方法和组合物 | |
| Lei et al. | Rapid generation of long, chemically modified pegRNAs for prime editing | |
| Yurina et al. | Mitochondrial genome structure of photosynthetic eukaryotes | |
| CN109790551A (zh) | 改进的基因编辑 | |
| CN107267516A (zh) | 双sgRNA介导的基因精确修饰方法及应用 | |
| US11634726B2 (en) | Cas9 nucleic acid molecules and their use | |
| Song et al. | RNA base editors: The emerging approach of RNA therapeutics | |
| KR102428773B1 (ko) | 분리형 crRNA 및 이를 이용한 CRISPR-Cas 시스템 | |
| JPWO2023014727A5 (https=) | ||
| JP2021533742A (ja) | 新規転写アクチベーター | |
| KR20220039564A (ko) | 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도 | |
| US20250064986A1 (en) | Optimized polynucleotides for protein expression | |
| EP4665406A1 (en) | Crispr-transposon systems and components | |
| WO2024137767A1 (en) | Compositions and methods for modifying dux4 | |
| CN117210435A (zh) | 一种用于调控rna甲基化修饰的编辑系统及其应用 | |
| CN115851793A (zh) | 一种高效表达猪pfkfb3基因的真核表达载体及其构建方法 |